CDK7 inhibitors as anticancer drugs

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and transcription.
• CDK7 activity is dysregulated in various cancers, making it a potential therapeutic target.
• Elevated CDK7 levels in cancers suggest a heightened dependence on its activity.

Purpose of the Study:

• To review the development of selective CDK7 inhibitors (CDK7i) for cancer treatment.
• To discuss the preclinical and clinical status of advanced CDK7i candidates.
• To explore the therapeutic potential of CDK7i as monotherapies and in combination regimens.

Main Methods:

• Development of selective CDK7 inhibitors.
• Preclinical evaluation of CDK7i efficacy, including cell cycle arrest, apoptosis, and transcriptional repression.
• Assessment of CDK7i in combination with other cancer therapies.
• Review of ongoing Phase I/II clinical trials for CDK7i.

Main Results:

• Selective CDK7 inhibitors demonstrate preclinical activity against diverse cancer types.
• CDK7i induce cell cycle arrest, apoptosis, and repress transcription, particularly of super-enhancer-associated genes.
• Combinations of CDK7i with other targeted therapies show efficacy in preclinical models.
• Four CDK7i (ICEC0942, SY-1365, SY-5609, LY3405105) are in Phase I/II clinical trials.

Conclusions:

• Selective CDK7 inhibitors represent a promising new class of cancer therapeutics.
• CDK7i show potential for overcoming resistance to existing cancer treatments.
• Further clinical investigation is warranted to establish the role of CDK7i in cancer therapy, both alone and in combination.